Onpattro availability?

Availability of Onpattro in the US Market

Onpattro, a prescription medicine, is indicated to treat polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis in adults [1]. However, its availability might be restricted due to patent protection.

When Does Exclusivity Expire?

The exclusivity for Onpattro, manufactured by Akcea Therapeutics, is set to expire in 2034, based on the patent and exclusivity information available on DrugPatentWatch.com [2]. This means that, after the exclusivity period, other companies may be able to market generic or biosimilar versions of Onpattro.

Why Are Some Companies Challenging Onpattro Patent?

Several companies, including Biogen, have challenged the patent for Onpattro, claiming infringement or seeking to invalidate the patent. This could potentially speed up the entry of generic or biosimilar versions into the market.

How Does Onpattro Compare to Other Treatments?

Onpattro is one of several treatment options available for hATTR amyloidosis. Other treatments, such as Tegsedi, a similar medication also used to treat polyneuropathy associated with hATTR amyloidosis, may have different characteristics and pricing.

Pricing and Accessibility

Onpattro's price has been a subject of discussion due to its high cost. Patients, healthcare providers, and payers have questioned the affordability and accessibility of the medication.

Sources:

[1] Onpattro (patisiran) Package Insert. Akcea Therapeutics.

[2] DrugPatentWatch.com. "Onpattro (patrisan) - DrugPatentWatch.com." Web. https://www.drugpatentwatch.com/drug/1134/onpattro-patisiran.

Note: This response only includes the sources cited within the response and is provided to enhance the accuracy of the information.